Tempest Therapeutics Secures $2.5M in Private Placement, Eyes $7.5M Total
Event summary
- Tempest Therapeutics raises $2.5M in private placement, with potential for $7.5M including warrant exercises.
- Deal includes 3.1M shares of common stock, Series C and D warrants at $0.805 per share.
- Proceeds earmarked for working capital and general corporate purposes.
- Closing expected September 14, 2026, subject to customary conditions.
- H.C. Wainwright & Co. acts as exclusive placement agent.
The big picture
Tempest Therapeutics' $2.5M private placement reflects the ongoing challenge for clinical-stage biotechs to secure non-dilutive funding amid volatile capital markets. The deal underscores the strategic importance of warrant structures in bridging financing gaps, particularly for companies developing next-generation therapies like in vivo CAR-T. The broader industry trend of targeted immune therapies continues to attract investor interest, though execution risks remain high.
What we're watching
- Execution Risk
- Whether Tempest can deploy proceeds effectively to advance its lead candidate, TPST-4003.
- Market Dynamics
- How the biotech financing landscape will impact future fundraising efforts for clinical-stage companies.
- Warrant Exercise
- The pace at which Series C and D warrants are exercised, determining the total funds raised.
Related topics